The cost-effectiveness of alternative strategies against HBV in Italy

Health Policy

Volumn 102, Issue 1, 2011, Pages 72-80

  Ruggeri, Matteo ^a   Cicchetti, Americo ^a   Gasbarrini, Antonio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

HBV; Markov model; Sceening test

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; TENOFOVIR;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; ITALY; MALE; MONTE CARLO METHOD; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; SCREENING TEST; SENSITIVITY ANALYSIS;

CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HUMANS; ITALY; LIVER CIRRHOSIS; LIVER NEOPLASMS; MASS SCREENING; MONTE CARLO METHOD; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; RISK MANAGEMENT; SENSITIVITY AND SPECIFICITY;

EID: 79960904521     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2010.09.012     Document Type: Article

References (46)

1. Ramzi S, Vinay K, Collins T. Le basi patologiche delle malattie. Vol. 1 [trad.] Mancini. A.M. VI. s.l.: Piccin, 2000.
2. Dienstag J.L. Hepatitis B virus infection. The New England Journal of Medicine 2008.
3. Lok A.S.F., McMahon B.J. Chronic hepatitis B. Hepatology 2007, 45(2):507-539.
4. Stroffolini T., Gaeta G.B., Mele A. AASLD practice guidelines on chronic hepatitis B and HBV infection in Italy. Hepatology 2007, 46(August (2)). 608-9.l.
5. Hoofnagle J.H, Doo E., Liang T.J., Fleisher R., Lock A.S.F. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007, 45(4).
6. Wright T.L., Lau J.Y. Clinical aspects of hepatitis B virus infection. Lancet 1993, 342(November):1340-1344.
7. Yiu-Kuen But D., Ching L.L., Man F.Y. Natural history of hepatitis-related hepatocellular carcinoma. World Journal of Gastroenterology 2008, 14(March (11)):1652-1656.
8. Heyward W.I., Lanier A.P., McMaban B., Kilkenny, Fitzgerald M.A., Paprocki T.R., et al. Screening for primary hepatocellular carcinoma among persons infected with hepatitis B virus. JAMA 1985, 254:3052-3054.
9. Kanwal F., Gralnek I.M., Martin P., Dulai G.S., Farid M., Spiegel B.M. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. The Americal Journal of Gastroenterology 2006, 101(September (9)):2076-2089.
10. Lahaye D., Strauss P., Baleux C., van Ganse W. Cost-benefit analysis of hepatitis-B vaccination. Lancet 1987, 22(August (2)):441-443.
11. Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Economics 2001, 10(December (8)):751-774.
12. Da Villa G., Sepe A. Immunization program against hepatitis B virus infection in Italy: cost-effectiveness. Vaccine 1999, 17(March (13-14)):1734-1738.
13. Sailly J.C., Lebrun T., Coudeville L. Cost-effective approach to the screening of HIV, HBV, HCV, HTLV in blood donors in France. Rev Epidemiol Santé Publique 1997, 45(April):131-141.
14. Corrao G., Zotti C., Tinivella F., Moiraghi Ruggenini A. HBV pre-vaccination screening in hospital personnel: cost-effectiveness analysis. European Journal of Epidemiology 1987, 3(March (1)):25-29.
15. Hutton D.W., Tan D., So S.K., Brandeau M.L. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Annals of Internal Medicine 2007, 147(October (7)):460-469.
16. Veldhuijzen I.K., Toy M., Hahné S.J., De Wit G.A., Schalm S.W., de Man R.A., et al. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. Gastroenterology 2010, 138(February (2)):522-530.
17. EASL Clinical Practice Guidelines, Journal of Hepatology 2010;53:397-417.
18. Fattovich G., Bortolotti D. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. Journal of Hepatology 2008, 48(2):335-352.
19. Tavole di mortalità per sesso ed età anno 1993-ISTAT.
20. Enriquez D., Campbell M.S., Reddy K.R. Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis. Alimentary Pharmacology and Therapeutics 2007, 26(August):383-391.
21. Sullivan S.D., Craxi A., Alberti A., Giuliani G., De Carli C., Wintfeld N., et al. Rapporto costo efficacia della terapia peginterferone alfa-2a+ribavirina in confronto a interferone alfa-2b+ribavirina in pazienti affetti da epatite cronica di tipo C precedentemente non trattati. PharmacoEconomics 2004, 6:105-114.
22. Kanwal F., Grainek M., Martin P., Dulai G.S., Farid M., Spiegel B.M.R. Treatment alternatives for chronic hepaties B virus infection: a cost effectiveness analysis. Annals of Internal Medicine 2005, 19(May):821-831.
23. Kanwal F., Gralnek I.M., Martin P., Dulai G.S., Farid M., Spiegel B.M.R. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. The Americal Journal of Gastroenterology 2006, 101(September (9)):2076-2089.
24. Carosi G., Rizzetto M. Treatment of chronic hepatitis B: recommendations from an Italian workshop. Digestive and Liver Disease 2008, 40:603-617.
25. Associazione Italiana per lo Studio del Fegato (AISF), Profilassi e terapia dell'epatite B nei pazienti immunocompromessi., Torino 2005.
26. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection, Journal of Hepatology, 46(1): 160-170.
27. Marzano A., Angelucci E., Androne P., Brunetto D., Bruno R., Burra P., et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Digestive and Liver Disease 2007, 39:397-408.
28. Barclay S., Pol S., Mutimer D., Bernhamou Y., Mills P.R., Hayes P.C., et al. The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting. Journal of Clinical Virolology 2008, 41(4):243-254.
29. Cooksley W.G.E., Piratvisuth T., Lee S.D., Mahachai V., Chao C., Tanwandee T., et al. Peginterferon alpha-2a (40kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. Journal of Viral Hepatitis 2003, 10(4):298-305.
30. Lau G.K.K. Peginterferon Alfa-2a, lamivudine, and the combination for. HBeAg-positive chronic hepatitis B. The New England Journal of Medicine 2005, 352(26):2682-2695.
31. Marcellin P., George K.K., Lau M.D. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. NEJM 2004, 351:1206-1217.
32. Dienstag Jl, Cianciara J., Karayalcin S., Kowdley K.V., Willems B., Plisek S., et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003, 37:748-755.
33. Hadziyanois Sj, Papathendotidis G.V., Latas A., Laras A., Papaioannou C. Efficacy of long term lamivudine-monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000, 32:847-851.
34. Peters M.G., Hann H.W.H., Martin P., Heathcote E.J., Buggisch P., Rubin R., et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004, 126:81-90.
35. Marcellin P., Chang T.T., Lim, Tong M.J., Sievert W., Shiffman M.L., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. The New England Journal of Medicine 2003, 348(9):808-816.
36. Chang T.T., Gish R.G., de Man R., Gadano A., Sollano J., Chao Y.C., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. The New England Journal of Medicine 2006, 354:1001-1010.
37. Ching L.L., Daniel S., Lok A.S.F., Chang T.T., Cheinquer H., Goodman Z., et al. Entecavir vs. lamivudine for patients with HBeAg-negative chronic hepatitis B. The New England Journal of Medicine 2006, 354(10):1011-1020.
38. Deniz B, Everhard F. Cost Effectiveness Simulation Analysis of Tenofovir Disoproxil Fumarate (TDF), Lamivudine (LAM), Adefovir Dipivoxil (ADV) and Entecavir (ETV) in HBeAg Negative Patients with Chronic Hepatitis B (CHB) in the USA 59th Annual Meeting of the American Association for the Study of Liver Diseases October 31-November 4, 2008 San Francisco, CA, USA.
39. http://www.uvef.it/web/?pag=schede-informative-sui-farmaci.
40. " Ricognizione e primo aggiornamento delle tariffe massime per la remunerazione delle prestazioni sanitarie" , issued on Gazzetta Ufficiale n. 289 del 13 dicembre 2006.
41. Ministero della Salute - Programmazione Sanitaria e Qualità leggi e documenti- Tariffario in euro delle prestazioni specialistiche, delle protesi e drg. Available at: http://www.ministerosalute.it/programmazione/normativa/sezNormativa.
42. Chapman R.H., Stone P.W., Sandberg E.A., Bell C., Neumann P.J., et al. A comprehensive league table of cost utility ratios and a sub-table of " panel worthy" studies. Medical Decision Making 2000, 20:451-467.
43. ISPOR, Country specific pharmacoeconomic guidelines, ISPOR 2006. Available at:. http://www.ispor.org/PEguidelines/index.asp.
44. Culyer A.J. NICE's use of cost-effectiveness as an example of deliberative process. Health Economics, Policy Law 2006, 1:299-318.
45. Garber A.M., Phelps C.E. Economic foundations of cost-effectiveness analysis. Journal of Health Economics 1997, 16:1-31.
46. Wu B., Li T., Chen H., Shen J. Cost effectiveness of nucleoside - analog therapy for Hepatitis B in China: a Markov analysis. Value in Health 2010, 13(5):592-600.